Clinical trial
Staccato Loxapine in Migraine (in Clinic)
NCT00489476 · Alexza Pharmaceuticals, Inc., Other · Completed
Key facts
| NCT number | NCT00489476 |
|---|---|
| Title | Staccato Loxapine in Migraine (in Clinic) |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Migraine Headache |
| Lead sponsor | Alexza Pharmaceuticals, Inc., Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Staccato Loxapine, Staccato Placebo |
| Enrollment | 168 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jun 21, 2007 |
| Last update posted | Jul 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: